Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) just unveiled an update.
On May 6, 2026, Tonix Pharmaceuticals said it had entered into an agreement, effective May 1, 2026, with a group purchasing organization that extends coverage for its drug TONMYA to roughly 35 million commercially insured individuals in the U.S. under standard utilization management criteria. The company also reported that TONMYA had already secured Medicaid coverage in 38 states, reaching about 55 million beneficiaries, marking a significant expansion of the drug’s reimbursement footprint across both commercial and public payers.
The dual coverage from a large commercial GPO and broad state Medicaid participation is poised to materially enhance patient access to TONMYA and could support increased prescription volumes and revenue visibility for Tonix. This expanded payer reach may also strengthen the company’s competitive positioning within its therapeutic category, as robust formulary inclusion is often a key determinant of prescriber uptake and market share, with implications for both investors and healthcare providers monitoring utilization trends.
The most recent analyst rating on (TNXP) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by very weak profitability and ongoing heavy cash burn, with additional pressure from bearish technicals. Positive recent corporate updates and a stronger, low-debt balance sheet provide some offset, but do not yet overcome the fundamental cash-flow and operating-loss profile.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing prescription medicines, including TONMYA, for the U.S. market. The company operates in the pharmaceutical industry with an emphasis on therapies that require broad payer coverage across commercial insurers and government programs to drive patient access and adoption.
Average Trading Volume: 397,157
Technical Sentiment Signal: Sell
Current Market Cap: $185.1M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.